NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (From Stocks News) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.15▼$3.5550-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume974,794 shsAverage Volume373,201 shsMarket Capitalization$111.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Edge Therapeutics alerts: Email Address Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. EDGE Stock News HeadlinesMay 16 at 2:13 PM | markets.businessinsider.com4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MAMay 14 at 9:45 AM | finance.yahoo.comATED Therapeutics Ltd. Finalist in Health Products Category of Fast Company’s 2024 World Changing Ideas AwardsMay 14 at 9:45 AM | markets.businessinsider.comTavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion TherapeuticsMay 12, 2024 | seekingalpha.comWhat Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerMay 12, 2024 | seekingalpha.comWhat Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerMay 10, 2024 | markets.businessinsider.comKey Takeaways From Relay Therapeutics Analyst RatingsMay 9, 2024 | finance.yahoo.comLisata Therapeutics Net Loss Declines From a Year EarlierMay 9, 2024 | finance.yahoo.comCB Therapeutics Introduces Sustainable Retinol ProductionMay 7, 2024 | finance.yahoo.comTopas Therapeutics Appoints Hugo Fry as CEOMay 7, 2024 | markets.businessinsider.comAtopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business UpdateMay 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy DataMay 2, 2024 | uk.finance.yahoo.comCorcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...May 2, 2024 | finanznachrichten.de500Newswire, LLC: CB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comCB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comKelonia Therapeutics to Participate in Upcoming Scientific ConferencesApril 30, 2024 | finance.yahoo.comAsimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development ServiceApril 29, 2024 | finanznachrichten.deEVOX THERAPEUTICS LIMITED: Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 29, 2024 | markets.businessinsider.comEvox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 26, 2024 | finance.yahoo.comRactigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBCApril 26, 2024 | msn.comMundipharma to acquire rezafungin assets from Cidara TherapeuticsApril 26, 2024 | msn.comFDA approves Utility Therapeutics’ Pivya tablets for UTIsApril 25, 2024 | finance.yahoo.comBiologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033April 24, 2024 | markets.businessinsider.comCutting-edge RM6 Million Laboratory Opens at UMMC to Advance Cancer TreatmentApril 23, 2024 | finance.yahoo.comRed Arrow Therapeutics Inc. closes $4.5M Seed Extension roundApril 22, 2024 | uk.finance.yahoo.comVect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and TumorsSee More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today5/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book3.72Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$111.23 million OptionableNot Optionable Beta3.65 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsPMV PharmaceuticalsNASDAQ:PMVPBeyondSpringNASDAQ:BYSIRezoluteNASDAQ:RZLTCorvus PharmaceuticalsNASDAQ:CRVSCyteir TherapeuticsNASDAQ:CYTTView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) issued its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.